<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00818597</url>
  </required_header>
  <id_info>
    <org_study_id>EISS-1</org_study_id>
    <nct_id>NCT00818597</nct_id>
  </id_info>
  <brief_title>Extracorporeal Immune Support System (EISS) for the Treatment of Septic Patients</brief_title>
  <acronym>EISS-1</acronym>
  <official_title>PhaseI/II Study of the Safety and Efficacy of the Use of Granulocyte-Concentrates Applied in Extracorporeal Circulation Devices-the EISS-1 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rostock</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rostock</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of an extracorporeal application of a
      bed-side bioreactor containing human donor granulocytes on the course and outcome of septic
      shock in humans.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>single organ functions (circulation, kidney, lung, liver)</measure>
    <time_frame>28day post inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>28day post inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Severe Sepsis and Septic Shock</condition>
  <arm_group>
    <arm_group_label>EISS-treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm patients receive additional treatment with the EISS-bioreactor</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EISS</intervention_name>
    <description>Two six hour-treatments with the EISS-Immune-cell bioreactor device within 72 hours post inclusion.</description>
    <arm_group_label>EISS-treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  sepsis with at least one organ failure (severe sepsis) or septic shock

        Exclusion Criteria:

          -  Participation in another study within the last 30 days

          -  Earlier participation in this study

          -  Pregnancy

          -  Bleeding, clinically not controlled (needing more than 2 red blood cell-transfusions
             per day)

          -  Hemodynamic shock for more than 12 hours (systolic BP &lt;90mmHg) despite adequate
             therapy

          -  HIV infection

          -  HCV infection, active
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Rostock, Department of Medicine, Division of Nephrology</name>
      <address>
        <city>Rostock</city>
        <zip>18055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.nephrologie.med.uni-rostock.de/</url>
  </link>
  <reference>
    <citation>Mitzner SR, Freytag J, Sauer M, Kleinfeldt T, Altrichter J, Klöhr S, Koball S, Stange J, Ringel B, Nebe B, Schmidt H, Podbielski A, Noeldge-Schomburg G, Schmidt R. Use of human preconditioned phagocytes for extracorporeal immune support: introduction of a concept. Ther Apher. 2001 Oct;5(5):423-32.</citation>
    <PMID>11778929</PMID>
  </reference>
  <reference>
    <citation>Sauer M, Altrichter J, Kreutzer HJ, Lögters T, Scholz M, Nöldge-Schomburg G, Schmidt R, Mitzner SR. Extracorporeal cell therapy with granulocytes in a pig model of Gram-positive sepsis. Crit Care Med. 2009 Feb;37(2):606-13. doi: 10.1097/CCM.0b013e318194aa77.</citation>
    <PMID>19114920</PMID>
  </reference>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2009</study_first_submitted>
  <study_first_submitted_qc>January 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2009</study_first_posted>
  <last_update_submitted>January 6, 2009</last_update_submitted>
  <last_update_submitted_qc>January 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Steffen Mitzner/ Head Division of Nephrology</name_title>
    <organization>University of Rostock, Medical Faculty</organization>
  </responsible_party>
  <keyword>septic shock</keyword>
  <keyword>immunoparalysis</keyword>
  <keyword>extracorporeal</keyword>
  <keyword>granulocyte bioreactor</keyword>
  <keyword>plasmapheresis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

